Clinical implications of breast cancer stem cells: A review.

Translational insights and clinical challenges of targeting cancer stem cells

Cancer stem cells (CSCs) are tumor cell subsets with self-renewal, multilineage differentiation, and tumor-initiating capacity that sustain cancer initiation, progression, metastasis, and relapse. Targeting CSCs therefore represents a promising route to improve the durability of cancer treatment. However, translation of this approach into routine care has been slow because of the biological complexity and clinical constraints. This review discusses current concepts of CSC origin and plasticity, the criteria used to define CSCs across different tumor types, and the marker systems as well as high-resolution technologies that are used to track CSC states. Developmental pathways, growth factor and cytokine cascades, as well as microenvironmental and stress responses that control CSC maintenance and therapy resistance are explored with a focus on their tractability as drug targets. We then discuss mechanisms through which CSCs escape chemotherapy, radiotherapy, and targeted agents. We review current efforts to use these pathways in designing small molecules, antibodies, cellular therapies, and vaccines aimed at CSC compartments. Heterogeneity within and between tumors, dynamic interconversion between CSC and non-CSC states, and support from specialized niches are considered as major barriers for clinical trial design, biomarker development, and response assessment. Emerging single-cell, spatial, and lineage tracing approaches, together with organoid and ex vivo platforms, are reviewed as tools that can bridge preclinical models and patient samples and guide the development of CSC-directed combination regimens. The goal is to outline translational principles that can guide future strategies for integrating CSC-focused interventions with established therapies to improve long-term disease control.

Breast cancer stem cells: drivers of progression and therapeutic resistance

Plastic features of BCSCs are summarized, their roles in metastasis and multidrug resistance, microenvironmental regulation and relevant therapeutic targeting strategies are summarized and progress toward subtype-specific combination approaches is indicated.

Cancer Stem Cells in Colorectal Cancer: From Molecular Mechanisms to Diagnosis, Prognosis and Therapy Implications

Simple Summary Colorectal cancer is often driven by a small population of colorectal cancer stem cells (CCSCs) that fuel tumor growth, metastasis, and treatment resistance, leading to relapse. These CCSCs are regulated by key signaling pathways, including Wnt/β catenin, Notch, Hedgehog, PI3K/AKT, MAPK/ERK, NF-κB, and TGF β, which are now being targeted by emerging drugs. CCSC markers and gene signatures are also under study as diagnostic and prognostic tools for early detection, minimal residual disease monitoring, and outcome prediction, although robust CCSC-specific assays and prospective clinical validation are still lacking. However, translating CCSC directed therapies into safe and effective treatments is difficult due to tumor heterogeneity, CCSC plasticity, compensatory pathways, and overlap with normal intestinal stem cell regulation. This review outlines CCSC biology, their biomarker potential, and current clinical trials targeting CCSC associated pathways, while highlighting major translational barriers that must be overcome.

Cell competition within breast tumor microenvironment: emerging role of cancer stem cells and immune cells in tumor progression and therapeutic implications

This review consolidates emerging evidence that positions cell competition as a critical regulator of clonal dynamics within the breast cancer TME and identifies competitive cellular fitness as a central and targetable driver of therapeutic resistance and tumor recurrence in breast cancer.

Identification of genes involved in breast cancer and breast cancer stem cells

Current therapeutic interventions to target cancer stem cells for metastasis